MacroGenics (NASDAQ:MGNX Shareholders Incur Further Losses as Stock Declines 16% This Week, Taking Three-year Losses to 82%
MacroGenics (NASDAQ:MGNX Shareholders Incur Further Losses as Stock Declines 16% This Week, Taking Three-year Losses to 82%
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in a while. So take a moment to sympathize with the long term shareholders of MacroGenics, Inc. (NASDAQ:MGNX), who have seen the share price tank a massive 82% over a three year period. That'd be enough to cause even the strongest minds some disquiet. The more recent news is of little comfort, with the share price down 28% in a year. Furthermore, it's down 73% in about a quarter. That's not much fun for holders. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.
地球上的每個投資者都會犯錯。 但是如果你經常面臨巨大的損失，那麼你就有了問題。 因此請花點時間同情MacroGenics，Inc. (納斯達克:MGNX)的長期股東，他們在三年內看到股價暴跌82％。 這足以使即使最強大的頭腦產生一些不安。 更近期的消息也不是很令人舒服，股價已下跌28％。 此外，約在一季度內下跌了73％。 這對持有者來說並不好玩。 我們真誠希望任何持有該公司股票的人都有分散投資組合。 即使你虧錢了，你也不必虧損教訓。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
考慮到過去一週對股東來說是艱難的，讓我們調查一下基本面並看看我們能學到什麼。
MacroGenics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.
MacroGenics目前沒有盈利，因此大多數分析師會尋找營收增長以了解其基礎業務增長速度。 一般來說，沒有盈利的公司預計每年都會增長收入，並且增長速度很快。 有些公司願意推遲盈利以加快收入增長，但在這種情況下，人們希望出現良好的頂線增長來彌補缺乏收益所帶來的影響。
Over the last three years, MacroGenics' revenue dropped 3.6% per year. That is not a good result. The share price fall of 22% (per year, over three years) is a stern reminder that money-losing companies are expected to grow revenue. This business clearly needs to grow revenues if it is to perform as investors hope. There's no more than a snowball's chance in hell that share price will head back to its old highs, in the short term.
在過去的三年中，MacroGenics的營業收入每年下降了3.6％。 這不是一個好結果。 每年股價下跌22％是一個嚴峻的提醒，表明預計虧損的公司需要增長收入。 如果這個公司要像投資者希望的那樣表現，它顯然需要增加收入。 短期內，股票回到舊高的可能性微乎其微。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以看到以下收益和營收的變化情況（通過單擊圖像了解精確值）。
MacroGenics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.
MacroGenics是一隻廣受關注的股票，擁有許多分析師的覆蓋，這表明未來增長的一些可見性。 鑑於我們有相當多的分析師預測數據，檢查這張描繪共識預測的免費圖表可能是值得的。
A Different Perspective
不同的觀點
MacroGenics shareholders are down 28% for the year, but the market itself is up 24%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 12% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand MacroGenics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for MacroGenics (of which 2 are a bit unpleasant!) you should know about.
MacroGenics的股東今年下跌了28％，但市場本身上漲了24％。 但是請記住，即使最好的股票有時也會在十二個月的時間內表現不佳。 不幸的是，去年的表現可能表明存在未解決的挑戰，因爲它比過去半個世紀的年化虧損12％還要糟糕。 我們意識到巴倫·羅斯柴爾德曾經說過投資者應該在“街頭流血”時買入，但我們警告投資者首先要確保他們正在購買高質量的企業。 跟蹤股票表現長期來看總是很有趣的。 但是要更好地了解MacroGenics，我們需要考慮許多其他因素。 如風險，例如。 每個公司都會面臨風險，我們已經發現MacroGenics有3個警告信號（其中2個有點不愉快！）你應該了解。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜歡與管理層一起購買股票，那麼您可能會喜歡這個公司的免費列表。 （提示：其中許多公司不爲人注意且具有吸引力的估值。）
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意，本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。